Abstract: This work takes advantage of one of the hallmarks of cancer,t hat is, the presence of tumor infiltrating cells of the immune system and leukocyte-secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP-RGD)w as found to accumulate on the surfaceo f a v b 3 integrin-expressing human renal cell carcinoma7 86-Oc ells. The ligand was conjugated to the anticancer drug paclitaxel throughaA sn-Pro-Val (NPV) tripeptide linker, which is as ubstrate of neutrophil-secreted elastase. In vitro linker cleavage assaysa nd cell antiproliferativee xperiments demonstrate the efficacy of this tumor-targeting conjugate, opening the way to potential therapeutic applications.
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The conjugation of anticancer drugs to specific ligands, capable of selectiveb inding to tumor-associated receptors, represents aw idely explored strategy to improve the accumulation of cytotoxic agentsa tt he tumor site, sparingh ealthy tissues and resulting in bettert herapeutic outcomes. Antibody-drug conjugates (ADCs) represent the first-in-class in this oncology area. [1] To date, four ADC products have gained marketing authorization (Adcetris,K adcyla,M ylotarg, and Besponsa), while more than 50 are presently under clinical investigation. [2] Similarly,a nticancer agents have also been coupled to small ligands (e.g.,p eptides/peptidomimetics, [3] vitamins, [4] steroids, [5] and enzymei nhibitors), [6] targeting specific receptors overexpressed by cancer cells. An increasing body of evidences suggests that these so-called smallm olecule-drug conjugates (SMDCs) [7] may accumulate in the tumor mass homogeneously and with high tumor/organ and tumor/blood ratios, potentially showingb etter anticancer efficacy than conventional cytotoxic agents and ADC products. [8] In general,t hese conjugates have been designed to bind the target receptor on the surface of cancer cells and to release the cytotoxic cargo in intracellular compartments (e.g.,l ysosomes), upon receptor-mediatedi nternalization and selectivec leavage of al inker (e.g.,ashort peptide sequence or ar educible disulfide bond) connecting the targeting unit to the payload. [9] Among the protein antigens that have been explored for tumort argetinga pplications, integrin a v b 3 is ah eterodimeric transmembrane receptoro verexpressed in av ariety of cancer types (such as melanoma, glioblastoma, renal cell carcinoma, and tumors of lung, ovary,b reast, prostate, and colon), where it is involved in disease progression. [10] Upon the observation that cyclic peptidesb earing the Arg-Gly-Asp( RGD) sequence are potential a v b 3 integrinl igands, al arge number of RGDbearingp eptides and peptidomimetics have been explored for SMDC development. [11] Within this frame, our group synthesized ac yclic peptidomimetic compound bearing the RGD integrin recognition motif and ad iketopiperazine (DKP) scaffold, as al ow nanomolar a v b 3 integrin ligand (compound 1,F igure 1). [12] The ligand wass uccessfully linked to different cytotoxic payloads (i.e.,p aclitaxel, [13] camptothecin, [14] and a-amanitin) [15] and the resulting conjugates maintained high affinity for the integrinr eceptor.I n line with literature data that reported evidenceo fi nternalization of integrin ligands equipped with fluorescent dyes, [16] our cyclo(DKP-RGD)-drug conjugates were endowed with suitable linkers for selective payload release in intracellular compartments of the cancerc ells. The ability of these SMDCs to selectively hit a v b 3 -positive cells was quantified through in vitro cell antiproliferative assays performed using cancer cell lines expressing the integrin receptor at different levels (i.e.,e xpressing vs. non-expressing cells). To our delight, some of these SMDCs provedt ob eh ighly selective for the a v b 3 -expressing cells, [17] indicating that 1 effectively recognizes the integrin re-ceptor on the cancerc ell membrane. However,t he potency of all our conjugates against a v b 3 -positive cells provedt ob es ignificantly lower (typically one order of magnitude)t han that of the free drug. This observation is in contrast with literature data reporting the high potency of internalizingA DCs and SMDCs, [18, 19] and it may indicate as uboptimal endocytosis of our ligand-drug conjugates. In order to confirm this hypothesis and evaluatet he internalization properties of the cyclo(DKP-RGD) integrin ligand,w el abeled it with the near-infrared( NIR) dye sulfo-cyanine5 (sCy5, Figure1). The ability of the resulting conjugate cyclo(DKP-RGD)-sCy5 (2)t oc ompetew ith biotinylated vitronectin for the bindingt ot he isolated a v b 3 receptor was measured. The low-nanomolar IC 50 value obtained confirmed that integrin recognition was not affected by the conjugation with the probe (2,F igure 1). Moreover, we devised the preparation of an egative control, possessing almost identical physical-chemical properties, while showing negligible affinity for the receptor.I nspired by the literature, [20] the Arg-Gly-Asp tripeptide was mutated into aA rg-[bAla]-Asp sequence, giving rise to the cyclo(DKP-RbAD) ligand 3 ( Figure 1 ). In comparison with the parent ligand 1,t he new compound showed ad ramatically lower integrin binding affinity (micromolar IC 50 value) and as imilar resultw as obtained for the fluorescent conjugate cyclo(DKP-RbAD)-sCy5 4 (Figure 1 ).
Confocal microscopy experiments were carried out with live human cancerc ells 786-O (renal cell carcinoma), expressing a v b 3 integrin (as detected by Western blot analysis;s ee Figure S1 in the Supporting Information), in the presence of conjugates 2 and 4.T he uncoupled sulfo-cyanine5 probe was also included in the experiment as additional control.A ss hown in Figure 2 , af air accumulationoft he cyclo(DKP-RGD)-sCy5 conjugate (2)onthe membrane of cancer cells was detected, whereas no significant intracellular uptake was observed. On the other hand, no accumulation of control compounds cyclo(DKPRbAD)-sCy5 (4)a nd free sulfo-cyanine5w as detected neither in intracellular compartments, nor on the cell surface.
Overall, this analysis confirmed that the integrin ligand cyclo(DKP-RGD) 1 accumulates on the cell membraneo fa v b 3 integrin-expressing cancer cells, while it is poorly internalizedb y receptor-mediatede ndocytosis. This finding may be relatedt o the antagonist behavior of 1,w hich has been found to display inhibitory effects on the FAK/Akti ntegrin-activated transduction pathway and on integrin-mediated cell infiltrationp rocesses. [21] The elucidation of the link between the agonist/antagonist behavior of integrin ligands and the receptor-mediated internalization is currently ah ot topic in this field. [22] Interestingly,the importance of conjugate internalization has been recently challenged.
[23] Indeed, ADCs and SMDCs specific to non-internalizing receptors (e.g.,c ollagen IV, [24] carbonic anhydrase IX, [25] fibrin, [26] and splice variants of fibronectin [27] and tenascin-C) [28] were found to elicit strong antitumorr esponses in vivo, while provings ignificantly less potent than the parent drug in in vitro cell antiproliferative assays. [29] For these reasons, we envisioned the preparation of an on-internalizing, a v b 3 integrin-targeted conjugate, featuring as pecific linker for the extracellularreleaseofthe payload.
In 2002, researchers at Bayer developedanew SMDC, whose linker consisted in the tripeptide Asn-Pro-Val (NPV), as pecific substrate of neutrophil elastase. [30] The latter is as erine pro- tease stored in azurophilic granules of neutrophilsa nd released into the extracellular space upon infections or inflammation stimuli. High levels of elastaseh ave been reported in primary tumors and metastasis, where it promotes oncogenic signaling and inhibits tumor suppressors. As ar esult, elevated neutrophil elastase levels correlate with poor prognosisi nd ifferent types of solidt umors. [31] To the best of our knowledge, no further investigations of this promising NPV peptidel inker have been reported in the literature. For these reasons, we designed an extracellularly cleavable conjugate (5,F igure 3) in which the a v b 3 integrinl igand cyclo(DKP-RGD) is connected to paclitaxel (PTX) via as elf-immolatives pacer,t he NPV linker and ah ydrophilicP EG4 spacer. Twoa dditional conjugates were prepared as negative controls:t he cyclo(DKP-RGD)-NPv-PTX conjugate (6), featuring the non-proteinogenic amino acid dvaline, and the cyclo(DKP-RGD)-unc-PTX conjugate (7), in which the tripeptide moietyi sr eplaced by ap roteolyticallys table (or "uncleavable") tertiarya mide bond. This panel of compounds was designed to gain insights into the specificity of elastase cleavage and the stability of the whole linker system.A ll synthetic details and analytics are included in the Supporting Information.
The affinity of compounds 5-7 for a v b 3 integrin was estimated as described previously and low-nanomolar values wereo btained throughout the series (Table 1) .
To evaluatet he cleavage of the tripeptide linker andt he subsequentp aclitaxel releasei nt he presence of neutrophil elastase, conjugate 5 was treated with the enzymeinP BS solution at 37 8C, andm etabolites were detected by HPLC-MSa nalysis. The enzymatic cleavage of the tripeptide linker was observed over a2hp eriod,r esulting in the complete formation of metabolite 10 [32] (Figure 3) , whereas the use of inactivated enzyme did not lead to metabolite formation ( Figure S2 in the Supporting Information).T he selectivity of linker cleavage was analyzed by treating 5 with rat liver-derived lysosome extract, composed of am ixture of proteolytic enzymes. The broadscope cysteine proteases inhibitorE -64 was used in this experiment to gain insight into the effector enzymes involved in the cleavage. Upon 2h exposure to lysosome extract, conjugate 5 was digested only partially ( Figure S4 in the Supporting Information),p ossibly indicatingt he presence of elastasei nt he lysosome extract. [33] This hypothesis was supported by the partial formation of metabolite 10 also in the presence of the E-64 inhibitor, ( Figure S4 in the Supporting Information) indicating that cysteinep roteases are not responsible for the cleavage of the NPV linker.
Additionally,c onjugate 5 was treated with mousep lasma at 37 8C, showinga ne xcellent stability under these conditions (t 1/2 = 35.3 h, Figure S5 in the SupportingI nformation).
Following the protocol reported by Bayer, [30] the in vitro cell antiproliferative activity of conjugates 5-7 was tested against 786-O cancer cells, in the presenceo ra bsence of elastase.I mportantly, Western blot analysis showed no significant elastase expression in these cancerc ells (see Figure S1 in the Supporting Information). This modela ssaya imed at evaluating the extracellularc leavage of the NPV linker upon activation of neutrophilsa nd releaseo fe lastase in the extracellular tumor environment,f ollowed by the PTX internalization into cancerc ells by passived iffusion throught he cell membrane. In the absence of elastase, conjugates 5-7 did not exhibit as ignificant cytotoxica ctivity (IC 50 > 5 mm, Ta ble 2), whereas free PTX inhibited cell proliferation at nanomolar concentrations( IC 50 = 35.8 AE 16.7 nm). Interestingly,c onjugate 5 displayed a > 250-fold increased activity (IC 50 = 19.6 AE 4.1 nm)u pon additiono f elastase (50 nm), and the observed potency was comparable to the one exhibited by free PTX under the same conditions (IC 50 = 29.5 AE 7.6 nm). On the other hand, the presenceo fe lastase did not modify the original cell antiproliferativea ctivity of conjugates 6 and 7.T his result indicates not only that the PTX payload is inactive when it is not released from the targeting vehicle, but also that the use of the natural amino acid l-Val at the linker C-terminus is crucial for the recognition of the tripeptides equence by elastase.
In conclusion, integrinl igands represent promising vehicles for the selective releaseo fa nticancer drugs at the tumor site. However,i ti ss till not clear whether different RGD-based ligands may have different effects on the receptor internalization and recycling in cancerc ells. Upon the observation that the integrin ligand cyclo(DKP-RGD) is not efficientlyinternalized by a v b 3 -expressing cancer cells, we focused on suitable strategies for the delivery of anticancer agentsi nt he extracellular tumore nvironment. In this work, the peptides equence NPV, substrate of the serine proteasee lastase, has been investigated as trigger for the release of paclitaxel from an a v b 3 -targeted conjugate. Ideally,t he integrin recognition unit would drive the conjugate accumulationa tt he tumor site, where the proinflammatory stimuli result in the recruitment of tumor-infiltrating leukocytes, such as neutrophils. The activation of the latter promotes the releaseo fe lastase, which triggerst he payload releaseinthe tumor microenvironment. As described elsewhere, [23] this mode of activation may possess potentialt herapeuticb enefits, since the free payload would diffuse in the tumorm ass, and act against al arge variety of cells (e.g.,a ntigen-negativec ancerc ells, endothelial and other cancer-associated host cells) leadingt oal ocalized damage. It has been reportedt hat lipophilic payloads are mosts uited for this strategy,a st he membrane permeability would facilitate the cytotoxic activity by the so-called" bystander effect." [34] Our in vitro data indicatet hat each individual unit of our SMDC (i.e., ligand,l inker,a nd drug) may efficiently act according to this ideal mechanism of action. Moreover,the pro-inflammatory environmenta nd the presence of infiltrating cells of the immune system are well-established hallmarks of cancers. [35] It is therefore conceivable that elastase-activatable prodrugs may be therapeutically active against al arge variety of tumor types. 
